Moderna, Pfizer, BioNTech, and AstraZeneca have all pledged to share their plans for their vaccine candidates in an effort to do everything they can do ensure transparency to avoid the political pressure of rushing the vaccines to the public. These companies have published information on their trial design, showcasing details about the trials that show what circumstances could generate efficacy results.
CEO of Moderna Stephane Bancel said, ““We have been working nine months to try to stop this virus by getting a vaccine to market. We want to make sure the general public has trust in vaccines by being transparent.” Moderna and other companies are trying to get their efficacy data in by November of this year as a best possible scenario. Their data plan involves looking at efficacy results after 53 trial participants have contracted Covid-19, and to check again after 106 cases. The final data check happens at 151 cases.
Bancel says it is highly unlikely that everyone in the United States will be able to receive a vaccine by the timeline that President Trump has outlined – the end of the first quarter of 2021.
This is a developing story so be sure to check back frequently at the ABN Blog.